This possibility, combined with the current analyses' emphasis on the role of cell cycle in ASPS, warrants further investigation for CHK1 inhibitors in the treatment of these chemo-resistant ASPS tumor cells. The gene discussed is CHEK1; the disease is alveolar soft part sarcoma.